Use of defibrinated blood for manufacture of hemoglobin-based oxygen carrier
US7553613B2 · kind B2 · utility
4Cited by
30References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 29, 2005 |
| Grant date | Jun 30, 2009 |
| Priority date | — |
| Expiry date | Jan 30, 2027 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/829
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Red blood cells are purified by defibrinating whole blood and then filtering the defibrinated whole blood, whereby at least a portion of a plasma component is separated from the red blood cells to form a suspension of red blood cells, thereby purifying the red blood cells. Whole blood is defibrinated by, for example, using a chemical coagulating agent or mechanical agitation. Separation of the plasma component from red blood cells can be completed by, for example, diafiltration. The suspension of red blood cells can then be employed to produce a hemoglobin-based oxygen carrier.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.